Document is current

Article History

Accepted: 27 July 2021

First Online: 17 August 2021

Declarations

:

: This work was funded by the Brain Aneurysm Foundation (VMT), NIH NINDS award R43 NS115314-0 (VMT), and the New York State Center for Advanced Technology in Big Data and Health Sciences (VMT).

: <i>VMT</i>—Principal investigator: National Science Foundation Award No. 1746694 and NIH NINDS award R43 NS115314-0; awardee of the abovementioned Brain Aneurysm Foundation grant, Center for Advanced Technology grant, and Cummings Foundation grant; co-founder: Neurovascular Diagnostics, Inc. <i>HZ</i>—None. <i>HR-O</i>—None. <i>LC</i>—None. <i>AAD</i>—None. <i>AHS</i>—Financial interest/investor/stock options/ownership: Adona Medical, Inc., Amnis Therapeutics, BlinkTBI, Inc., Boston Scientific Corp. (for purchase of Claret Medical), Buffalo Technology Partners, Inc., Cardinal Consultants, LLC, Cerebrotech Medical Systems, Inc., Cognition Medical, Endostream Medical, Ltd, Imperative Care, Inc., International Medical Distribution Partners, Neurovascular Diagnostics, Inc., Q’Apel Medical, Inc., Radical Catheter Technologies, Inc., Rebound Therapeutics Corp. (purchased 2019 by Integra LifeSciences, Corp.), Rist Neurovascular, Inc., Sense Diagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, Spinnaker Medical, Inc., StimMed, Synchron, Three Rivers Medical, Inc., Vastrax, LLC, VICIS, Inc., Viseon, Inc.; consultant/advisory board: Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA, Inc., Cerebrotech Medical Systems, Inc., Cerenovus, Corindus, Inc., Endostream Medical, Ltd, Imperative Care, Inc., Integra LifeSciences Corp., Medtronic, MicroVention, Minnetronix Neuro, Inc., Northwest University – DSMB Chair for HEAT Trial, Penumbra, Q’Apel Medical, Inc., Rapid Medical, Rebound Therapeutics Corp., Serenity Medical, Inc., Silk Road Medical, StimMed, Stryker, Three Rivers Medical, Inc., VasSol, W.L. Gore & Associates; national PI/steering committees: Cerenovus LARGE Trial and ARISE II Trial, Medtronic SWIFT PRIME and SWIFT DIRECT Trials, MicroVention FRED Trial & CONFIDENCE Study, MUSC POSITIVE Trial, Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial; research grants: co-investigator: NIH/NINDS 1R01NS091075 Virtual Intervention of Intracranial Aneurysms; role: co-principal investigator: NIH-NINDS R21 NS109575-01 Optimizing Approaches to Endovascular Therapy of Acute Ischemic Stroke. <i>JK</i>—None. <i>KEP</i>—None.

: Not applicable; this study was a reanalysis of previously collected, banked, publicly available data.

: Not applicable; this study was a reanalysis of previously collected, banked, publicly available data.

: Not applicable; this study was a reanalysis of previously collected, banked, publicly available data.

: All data can be found at the Gene Expression Omnibus, under dataset GSE122897.

: Not applicable; all computational analyses were performed using standard, published/available codes and software.

: VMT and KEP conceived and designed the research. VMT, HZ, KEP, and AHS collected and reviewed the data. VMT, HZ, HR-O, LC, and KEP analyzed the data and performed the statistical analysis. VMT and KEP handled the funding and supervision of the research. VMT and KEP drafted the manuscript. VMT, HZ, HR-O, LC, AAD, AHS, JK, and KEP revised the manuscript and reviewed the final version.